Additional file 1: of Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial

Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Checklist: recommended items to address in a clinical trial protocol and related documents*. Additional file 1: of Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial. (DOCX 50 kb

Comparison between the determinate and indeterminate QFT-GIT result groups using logistic regression analysis.

<p>Comparison between the determinate and indeterminate QFT-GIT result groups using logistic regression analysis.</p

Additional file 1: of Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

Figure S1. Distribution plots of the 65 cytokines targeted by the Discovery assay. Boxplot graphs showing relative fluorescence intensity (RFU; y axis) of the plasma samples (X) for (a), 60 of the 65 cytokines that were within the range of the external standards (from known low (S1) to high (S7) concentrations) while (b). 5 of the 65 cytokines were out of the standard curve range. Blank (B) values were also included in the assay. Figure S2. Distribution plots of five cytokines detected below the standard curve range in the Discovery assay. Histogram graphs showing distribution of the relative fluorescence units (RFU) of 47 plasma samples for Eotaxin-3, IL-21, IL-3, IL-9 and TSLP. Figure S3. Correlation of high and low abundance proteins. Median RFU of highly abundant proteins CTACK and Eotaxin-1, and low abundance proteins IL-7 and I-309 from the SOMAscan and Discovery assays were plotted; each point corresponds to a different patient sample (PRE and EDT plasmas). Proteins that are high and low abundance show poor correlation between the two assays. (DOCX 1640 kb

Patient characteristics before and after propensity score matching.

<p>Patient characteristics before and after propensity score matching.</p

Baseline characteristics of enrolled population.

<p>Baseline characteristics of enrolled population.</p

Relationship between indeterminate QFT-GIT results and diabetes mellitus using multivariable logistic regression and propensity score matched analysis.

<p>Relationship between indeterminate QFT-GIT results and diabetes mellitus using multivariable logistic regression and propensity score matched analysis.</p

Flow chart of the study protocol.

<p>We screened 3,571 subjects who underwent QuantiFERON-TB Gold In-Tube testing (QFT-GIT) testing more than once. Of these subjects, patients who were under 18 years old (n = 127) or who underwent QFT-GIT more than twice without consistent results (n = 53) were excluded. After exclusion, 3,391 patients were enrolled in the study in which 1,265 (37.3%) had a positive QFT-GIT result, 266 (7.8%) had an indeterminate result, and 1,860 (54.9%) had a negative result.</p